Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2226 - 2250 of 15512 in total

Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. ... Clinical manifestations of MF include anemia and thrombocytosis. ... MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Donislecel

Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and …
Matched Categories: … Cellular and Gene Therapy …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Iupac: … (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane- …
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Methotrimeprazine

A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)
Approved
Investigational
Matched Description: … A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine …

Onasemnogene abeparvovec

Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … to debilitating and often fatal muscle weakness. ... for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and ... complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing ... [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. ... IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eflapegrastim

Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … risk of morbidity and mortality. ... Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia ... [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Alteplase

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase...
Approved
Investigational
Matched Description: … alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and ... thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and ... alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Ammonia N-13

Ammonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3 with a molecular weight of 16.02. Ammonia N 13 Injection, USP is used for imaging...
Approved

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Approved
Matched Description: … It is 140 residues long, and is produced using E. coli. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Guanethidine

An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]
Approved
Matched Description: … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes …
Matched Categories: … guanethidine and diuretics ... Antiglaucoma Preparations and Miotics ... Guanidine Derivatives and Diuretics …

Isatuximab

Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the...
Approved
Investigational
Matched Description: … L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and ... dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Alpha-1-proteinase inhibitor

Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
Approved
Matched Description: … inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Isopropamide

Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility.
Approved
Vet approved
Matched Iupac: … (3-carbamoyl-3,3-diphenylpropyl)(methyl)bis(propan-2-yl)azanium …
Matched Description: … and hypermotility. ... It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity …
Matched Categories: … Alimentary Tract and Metabolism ... isopropamide and psycholeptics …

Bimekizumab

Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor,...
Approved
Investigational
Matched Description: … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F. ... compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and ... of moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Vecuronium

Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other...
Approved
Investigational
Matched Description: … as well as its short duration of action and easy reversibility provide advantages over, or alternatives ... Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination …

Fesoterodine

Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
Approved
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Olaparib

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib...
Approved
Matched Iupac: … 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one …
Matched Description: … Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and ... [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health ... [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Interferon beta-1b

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Rimonabant

Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved...
Approved
Investigational
Matched Iupac: … 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide …
Matched Description: … Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. ... Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. ... . advisory panel recommended the medicine not be approved because it may increase suicidal thinking and …
Matched Categories: … Cannabinoids and similars ... Alimentary Tract and Metabolism ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Oxazepam

Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine lorazepam, is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in...
Approved
Matched Description: … [A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little ... Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and ... factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Oxyphencyclimine

Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.
Approved
Matched Iupac: … (1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate …
Matched Categories: … Alimentary Tract and Metabolism ... oxyphencyclimine and psycholeptics …

Selumetinib

Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming. However,...
Approved
Investigational
Matched Iupac: … 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-1,3-benzodiazole-6-carboxamide …
Matched Description: … [A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading ... Luckily, the use of selumetinib in patients with NF-1 have shown efficacy in shrinking associated tumours and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Catridecacog

Coagulation Factor XIII A-Subunit (Recombinant), also known as catridecacog, is a recombinant form of the Factor XIII-A2 homodimer composed of two factor XIII (FXIII) A-subunits [FDA Label]. For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential...
Approved
Matched Description: … and maintenance of hemostasis [A18581]. ... , including hydrophobic interaction and ion exchange chromatography [FDA Label]. ... in increased mechanical strength and resistance to fibrinolysis of the fibrin clot. …
Matched Categories: … Blood and Blood Forming Organs …
Displaying drugs 2226 - 2250 of 15512 in total